Gramercy Extremity Orthopedics (GEO) announced FDA 510(k) clearance of its distal fibular ankle fracture plating system and its Multi-Application Extremity Plating System.
These new plates integrate with GEO’s current system, utilizing the same single-use sterile instrument kits and screws that are brought to market with the GEO Cart.
GEO CART is a proprietary point-of-sale system, comprising a computerized mobile implant and instrumentation inventory system based on RFID Technology.
“Orthopedics, and by default healthcare in the United States, is at an inflection point. We are excited to offer leadership in our space, which is now being driven by the demand for traceable and efficient instrument and implant delivery models,” said Michael Simpson, GEO’s Chief Executive Officer. “In expanding our product offering with these two new lines, we are better positioned to partner with our IDNs, health systems, and surgery centers. GEO will continue to redefine what we believe is the future of sustainable patient care and to support our surgeons in their essential work.”
Gramercy Extremity Orthopedics (GEO) announced FDA 510(k) clearance of its distal fibular ankle fracture plating system and its Multi-Application Extremity Plating System.
These new plates integrate with GEO's current system, utilizing the same single-use sterile instrument kits and screws that are brought to market with the GEO Cart.
GEO CART...
Gramercy Extremity Orthopedics (GEO) announced FDA 510(k) clearance of its distal fibular ankle fracture plating system and its Multi-Application Extremity Plating System.
These new plates integrate with GEO’s current system, utilizing the same single-use sterile instrument kits and screws that are brought to market with the GEO Cart.
GEO CART is a proprietary point-of-sale system, comprising a computerized mobile implant and instrumentation inventory system based on RFID Technology.
“Orthopedics, and by default healthcare in the United States, is at an inflection point. We are excited to offer leadership in our space, which is now being driven by the demand for traceable and efficient instrument and implant delivery models,” said Michael Simpson, GEO’s Chief Executive Officer. “In expanding our product offering with these two new lines, we are better positioned to partner with our IDNs, health systems, and surgery centers. GEO will continue to redefine what we believe is the future of sustainable patient care and to support our surgeons in their essential work.”
Copy to clipboard 
